Home
Home

cabozantinib

Where Is Exelixis In The Cancer Therapeutics Market?

Where Is Exelixis In The Cancer Therapeutics Market?
Seeking Alpha

Exelixis' Crowning Achievement

Exelixis' Crowning Achievement
Motley Fool

Exelixis Traders Brace For Upcoming FDA Decision

Exelixis Traders Brace For Upcoming FDA Decision
Seeking Alpha

2 Important Decisions to Watch For This Week in the Biotech Sector

2 Important Decisions to Watch For This Week in the Biotech Sector
Motley Fool

Exelixis's Cabozantinib Should Receive FDA Approval, But Faces Long-Term Challenges

Exelixis's Cabozantinib Should Receive FDA Approval, But Faces Long-Term Challenges
Seeking Alpha

Exelixis Stock Treads Water Ahead Of FDA Decision

Exelixis Stock Treads Water Ahead Of FDA Decision
Seeking Alpha

ArQule's Tivantinib Failure And Exelixis' Cabozantinib PDUFA: Is There A Correlation?

ArQule's Tivantinib Failure And Exelixis' Cabozantinib PDUFA: Is There A Correlation?
Seeking Alpha

Preliminary Phase 1 Data for Cabozantinib in Japanese Patients Presented at ESMO 2012

Preliminary Phase 1 Data for Cabozantinib in Japanese Patients Presented at ESMO 2012
Yahoo/BusinessWire

Exelixis Provides Update on ODAC Panel for Cabozantinib

Exelixis Provides Update on ODAC Panel for Cabozantinib
Yahoo

FDA Grants Priority Review for Cabozantinib in Medullary Thyroid Cancer

FDA Grants Priority Review for Cabozantinib in Medullary Thyroid Cancer
Yahoo